March 15 (Reuters) - Aralez Pharmaceuticals Inc ARZ.TO :
* Has resubmitted to U.S. FDA NDA for its investigational
candidate Yosprala
Source text for Eikon: ID:nPn3M9hpLa
Further company coverage: ARZ.TO
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)